Blood Rivals

Blood Rivals is a first-person battle royale where you have to try to kill all your rivals and make it out as the sole survivor. To do it you use an enormous arsenal of pistols, knives, shotguns, axes, and assault rifles. And all in 10-minutes rounds.

Blood & Alchemy is an expansion for Vampire: The Masquerade Rivals Expandable Card Game that adds two new clans: Tremere & Thin-bloods. The Tremere are masters of Blood Sorcery who draw incredible power from their Blood, while the Thin-bloods must mix a plethora of chemicals with their Blood to extract power from it. You may play these two clans head-to-head or simply integrate them with your Core Set to give you more options for mixing clans and creating new decks!

Blood Rivals

Download Zip 🔥 https://urlin.us/2y2FAh 🔥

When the sun sets, the undead awaken. To slake their Hunger, they feed upon the herd of unaware mortals. Right beneath our noses, the Kindred clash against their rivals as they vie for control of the...

Robert Pattinson and Taylor Lautner : read all about these two teen heartthrobs and how they have learned to stay grounded throughout their meteoric rise to fame, while the entire world is thirsting for their blood. Vampire or werewolf, Team Edward or Team Jacob - whose side are you on?

Red Cross HBCU Ambassador Alexis Powell (left) thanks Jayla Tolbert, a senior nutrition and dietetics student at Alabama A&M, for rolling up a sleeve to give blood. Red Cross Photo by Tiffany Taylor

Jayla Farr, a whole blood donor, makes her first Power Red donation at the Magic City Classic Blood Drive at Alabama State. A special machine allows her to donate two units of red blood cells during one donation. Red Cross Photo by Tiffany Taylor

Malachi Williams (left) and Eric Thompson, Alabama State students and members of the National Pan-Hellenic Council, greet and help sign in presenting blood donors at the Magic City Classic Blood Drive. Red Cross Photo by Tiffany Taylor

Since 2017, the Alabama A&M University Bulldogs and Alabama State University Hornets have teamed up with the American Red Cross to kick off their historic rivalry to see who can recruit the most blood donors ahead of the annual Magic City Classic football game at Legion Field in Birmingham, AL.

Partnerships and collaborations with organizations like the Red Cross have been a part of the core values of HBCUs for many years. Educational institutions like Alabama A&M and Alabama State use things like hosting campus blood drives as opportunities to contribute to the development of their students while making a broader community impact.

For many students who attended high school remotely during the pandemic, campus blood drives like the Magic City Classic Blood Drive offer a convenient opportunity to give blood for the first time, and to do so with friends.

To date, the Magic City Classic Blood Drive has collected more than 975 units of lifesaving blood for patients. (A blood drive was not held in October 2020 due to COVID restrictions on campus activities and events.) Yet, the philanthropic legacies of students promoting blood donation at Alabama A&M and Alabama State began years before the first Magic City Classic Blood Drive.

Since the early 2000s, student organizations, athletic programs and undergraduate membership organizations of the National Pan-Hellenic Council have hosted Red Cross blood drives on each of their campuses, resulting in over 2,225 blood donations collected to date (including units collected at Magic City Classic Blood Drives).

Blood donations from the Magic City Classic Blood Drive come as the Red Cross has an urgent need for eligible donors of all blood types, especially those with Type O blood. African Americans make up 51% of individuals with Type O blood. Therefore, the impact of this blood drive on accident and burn victims, heart surgery patients, organ transplant patients, and those receiving treatment for leukemia, cancer or sickle cell disease is tremendous.

These four Red Cross HBCU Ambassadors are learning how to lead blood drive planning efforts by securing additional incentives such as food and entertainment, collaborating with student organizations, raising awareness about blood donation and sickle cell disease all while prioritizing a goal to increase blood donations to help patients.

The American Red Cross shelters, feeds and provides comfort to victims of disasters; supplies about 40% of the nation's blood; teaches skills that save lives; distributes international humanitarian aid; and supports veterans, military members and their families. The Red Cross is a nonprofit organization that depends on volunteers and the generosity of the American public to deliver its mission. For more information, please visit redcross.org or cruzrojaamericana.org, or visit us on Twitter at @RedCross.

By Bill Berkrot and Ransdell Pierson DALLAS (Reuters) - A new blood clot and stroke preventer from Daiichi Sankyo proved as effective and safer than widely used warfarin in a large, late stage trial of patients with atrial fibrillation, paving the way for it to compete with other new warfarin alternatives on the market. The drug, edoxaban, met the main efficacy and safety goals of the study by demonstrating "non-inferiority" to warfarin in preventing strokes and blood clots and led to significantly less major bleeding - the greatest danger of blood thinning medicines. The trial, dubbed Engage AF, tested two doses of edoxaban against warfarin in 21,105 patients with atrial fibrillation - a dangerously irregular heartbeat - at moderate to high risk of stroke. It followed patients on average for nearly three years, making it the largest and longest study to date of any of the new generation of blood thinners. Results of the trial were presented on Tuesday at the American Heart Association scientific meeting in Dallas. Atrial fibrillation, which affects nearly three million Americans and makes them five times more likely to suffer a stroke, is seen as the most important use for these drugs. Edoxaban is already sold in Japan under the brand name Lixiana and Daiichi said it plans to file its application seeking U.S. approval in the first quarter of 2014. The company will seek approval to market the medicine for venous thromboembolism, blood clots that form in the veins. "Personally, I think it will be used. We know this drug is safer than warfarin," said the study's lead investigator, Dr. Robert Giugliano, a cardiologist at Brigham and Women's Hospital in Boston. But it will enter a market that already has three other new medicines vying to displace cheap, decades-old warfarin. It aims to compete with Xarelto, sold by Bayer AG and Johnson & Johnson, and Eliquis sold by Bristol-Myers Squibb Co and Pfizer Inc, which belong to the same class of drugs as edoxaban, as well as a similar medicine from Boehringer Ingelheim called Pradaxa. Industry analysts believe the new blood thinners could eventually generate sales of more than $10 billion a year. But without any head-to-head trials that can definitively show one of the novel anticoagulants is better than another, this will likely come down to a marketing war among pharmaceutical heavyweights. "We see an uphill battle for edoxaban and do not expect the product to meaningfully change market dynamics in the atrial fibrillation space," JP Morgan analyst Chris Schott said in a research note. Dr. Mark Link, a professor at Tufts University Medical Center in Boston, who was not involved in the trial, said: "If you look at the four new drugs, they're more similar than different. All these drugs are safer than warfarin." TAKEN ONCE A DAY One potential differentiator is that edoxaban and Xarelto are once a day pills, while Eliquis and Pradaxa are taken twice a day. Sixty-year-old warfarin works well in preventing strokes, but is notoriously difficult to use. It requires careful monitoring of patients' blood levels, dose adjustments and dietary changes. The new drugs, while more expensive for patients, have several advantages. "They're safer, more convenient to use and there's no need for monitoring," said Giugliano, who presented the data at the meeting. "These drugs dramatically reduce bleeding in the brain. They are saving lives," he added. The edoxaban trial tested two doses of the drug - 60 milligrams and 30 mg - against warfarin. In an effort to more mirror likely real world use, the study allowed for dose reductions for factors such as kidney function impairment or patients of particularly low weight. About a quarter of edoxaban patients had the dose cut in half after starting the trial, researchers said. Overall, the higher dose of edoxaban reduced stroke and blood clots by 21 percent compared with warfarin, which was deemed to be non-inferior - the study's intended goal - but fell just shy of superiority. The lower dose was not as effective due to much higher incidence of ischemic strokes, caused by blockages of blood vessels. But for the more troubling hemorrhagic strokes, which often involves fatal brain bleeding, edoxaban was far better than warfarin. Those were reduced by 46 percent in the higher dose group and by 67 percent for the low dose versus warfarin. Overall, major bleeding was reduced by 20 percent versus the older medicine with the higher edoxaban dose and by 53 percent for the lower dose, which was considered highly statistically significant, researchers said. Significantly fewer edoxaban patients died from heart related causes. Death for any reason was significantly lower for low dose edoxaban and numerically lower for the high dose of the Daiichi drug, but that was not statistically significant, researchers said. "I think it's good news for the patients and good news for health care providers. You can feel very secure when you have over 21,000 patients in a trial and followed for almost three years," said Giugliano. "This trial was extraordinarily well done," said Dr. Nathaniel Reichek, director of research at St. Francis Hospital in Roslyn, New York, who was not involved in the study. "Edoxaban seems clearly like it's going to be a competitor." (Reporting by Bill Berkrot and Ransdell Pierson; Editing by Nick Zieminski, Bernard Orr) ff782bc1db